BeOne Medicines (ONC) Operating Income (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Operating Income of $249.9 million for Q1 2026, up 2150.96% year-over-year from $11.1 million in Q1 2025, and up 35.06% quarter-over-quarter from $185.0 million in Q4 2025.
BeOne Medicines (ONC) Operating Income (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Operating Income for 12 consecutive years, with $249.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 2150.96% year-over-year to $249.9 million; the TTM figure through Mar 2026 stood at $685.9 million (up 331.93% YoY), while the FY2025 annual figure was $447.1 million, up 178.69% from the prior year.
- Operating Income climbed to $249.9 million in Q1 2026 per ONC's latest filing, from $185.0 million in the prior quarter.
- Across five years, Operating Income topped out at $249.9 million in Q1 2026 and bottomed at -$468.6 million in Q4 2022.
- Historically, Operating Income has averaged -$168.7 million across 5 years, with a median of -$134.0 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 731.76% — and 2026, when it soared 2150.96%.
- BeOne Medicines' Operating Income stood at -$468.6 million in 2022, then advanced by 18.1% to -$383.8 million in 2023, then jumped by 79.31% to -$79.4 million in 2024, then jumped by 332.97% to $185.0 million in 2025, then soared by 35.06% to $249.9 million in 2026.
- Business Quant data shows ONC's Operating Income at $249.9 million in Q1 2026, $185.0 million in Q4 2025, and $163.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 325.05 Mn |
| Mar 31, 2026 | 249.90 Mn |
| Dec 31, 2025 | 185.04 Mn |
| Sep 30, 2025 | 163.11 Mn |
| Jun 30, 2025 | 87.89 Mn |
| Mar 31, 2025 | 11.10 Mn |
| Dec 31, 2024 | -79.43 Mn |
| Sep 30, 2024 | -120.27 Mn |
| Jun 30, 2024 | -107.16 Mn |
| Mar 31, 2024 | -261.35 Mn |
| Dec 31, 2023 | -383.80 Mn |
| Sep 30, 2023 | -133.97 Mn |
| Jun 30, 2023 | -318.72 Mn |
| Mar 31, 2023 | -371.26 Mn |
| Dec 31, 2022 | -468.62 Mn |
| Sep 30, 2022 | -438.36 Mn |
| Jun 30, 2022 | -439.40 Mn |
| Mar 31, 2022 | -443.29 Mn |
| Dec 31, 2021 | 190.56 Mn |
| Sep 30, 2021 | -462.33 Mn |